GSK has announced a $1.4 billion acquisition of Aiolos Bio, including a $1 billion upfront payment, to secure AIO-001, a promising long-acting anti-TSLP antibody for severe asthma treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.